Oxolipidomics profile in major depressive disorder: Comparing remitters and non-remitters to repetitive transcranial magnetic stimulation treatment.

ABSTRACT:

Background

Repetitive Transcranial Magnetic Stimulation [rTMS] is increasingly being used to treat Major Depressive Disorder [MDD]. Given that not all patients respond to rTMS, it would be clinically useful to have reliable biomarkers that predict treatment response. Oxidized phosphatidylcholine [OxPC] and some oxylipins are important plasma biomarkers of oxidative stress and inflammation. Not only is depression associated with oxidative stress, but rTMS has been shown to have anti-oxidative effects.

Objectives

To investigate whether plasma oxolipidomics profiles could predict treatment response in patients with treatment resistant MDD.

Methods

Fourty-eight patients undergoing rTMS treatment for MDD were recruited along with nine healthy control subjects. Plasma OxPCs

SUBMITTER: Stirton H 

PROVIDER: S-EPMC7877633 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature